psalexa
logo

Acne Vulgaris Therapeutics Pipeline Analysis, 2017

Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11275
Available Format:
Pages: 141

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Acne vulgaris develops on the face and upper trunk and most often affects adolescents. The causes of the acne include excess oil production, clogging of air follicles by oil and dead skin cells, and excess activity of androgens. Acne vulgaris is characterized by the occurrence of comedones, papules, pustules, nodules, and/or cysts due to obstruction and inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). Sol-Gel Technologies Ltd. is in the process of research and development of three products for the treatment of acne vulgaris. PR023 is in early stages of development by the Realm Therapeutics, Inc. for the treatment of acne vulgaris. Increased early stage drug candidates and positive clinical trial results of the drugs being developed by the different pharmaceutical companies, are the major drivers for the acne vulgaris pipeline.

 

ACNE VULGARIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
ACNE VULGARIS THERAPEUTICS DRUG
 

Pipeline Analysis

As of November 2017, the acne vulgaris therapeutics pipeline comprises of 49 drug candidates in different stages of development.

Competitive Landscape

Some of the players developing drugs for the treatment of acne vulgaris include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry